Efficacy and safety of drug-eluting bead bronchial arterial chemoembolization plus anlotinib in patients with advanced non-small-cell lung cancer
J Liu, W Zhang, J Ren, Z Li, H Lu, Z Sun… - Frontiers in Cell and …, 2021 - frontiersin.org
Aim: The aim of this study is to determine the efficacy and safety of the combination therapy
of drug-eluting bead bronchial arterial chemoembolization plus anlotinib oral administration …
of drug-eluting bead bronchial arterial chemoembolization plus anlotinib oral administration …
[HTML][HTML] Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review …
Z Wu, P Zhou, Y Zhao, J Wang… - Translational Cancer …, 2024 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) remains a leading cause of cancer
mortality. Combined anlotinib and immune checkpoint inhibitors (ICIs) therapy may have …
mortality. Combined anlotinib and immune checkpoint inhibitors (ICIs) therapy may have …
Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma …
YJ Wang, KK Li, XF Xie, T Bao, ZP Hao, J Long… - Frontiers in …, 2022 - frontiersin.org
Background Clinical benefits of neoadjuvant Anlotinib for locally advanced esophageal
squamous cell carcinoma (ESCC) remains unclear. This study evaluated the efficacy and …
squamous cell carcinoma (ESCC) remains unclear. This study evaluated the efficacy and …
[HTML][HTML] Anlotinib in Chinese patients aged≥ 70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm …
D Zhao, Z Li, X Hou, L Yang, Z Li, L Yan, H Li… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Background Based on pharmacoeconomics, drug availability and actual treatment, optimal
treatment regimens for Chinese non-small-cell lung carcinoma (NSCLC) patients over 70 …
treatment regimens for Chinese non-small-cell lung carcinoma (NSCLC) patients over 70 …
[HTML][HTML] Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 …
Y Liu, L Miao, X Chen, X Zhu, Y Li, J He, P Chen, S Dai… - Medicine, 2024 - journals.lww.com
Background: Maintenance therapy could significantly improve the prognosis of patients with
advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Anlotinib is …
advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Anlotinib is …
Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report
J Wang, X Li, J Zhou, D Qiu, M Zhang, L Sun… - Frontiers in …, 2023 - frontiersin.org
Background Half of the population of non-small cell lung cancer (NSCLC) patients are older
than 70 years and have limited therapeutic options due to poor tolerance and being …
than 70 years and have limited therapeutic options due to poor tolerance and being …
Case report: Long-term survival with anlotinib in a metastatic parathyroid carcinoma patient harboring EGFR-sensitizing mutation
Y Ying, H Li, W Xia, T Cheng, H Li, Q Fu, T Ai, Y Yang… - 2023 - researchsquare.com
Parathyroid carcinoma (PC) is a rare and aggressive endocrine malignancy with limited
treatment options. Despite the lack of standard management approaches to prevent …
treatment options. Despite the lack of standard management approaches to prevent …